Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Twist Bioscience Corporation (TWST) Tops Q1 EPS by 2c, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus
February 4, 2021 4:55 PM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($0.72), $0.02 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $28.2 million versus the consensus estimate of $25.38 million.
FISCAL 2021 FIRST QUARTER FINANCIAL RESULTS
Orders: Total orders received for the first quarter of fiscal 2021 were $33.6 million, compared to $24.8 million for the same period of fiscal 2020.Revenue: Total revenues were $28.2 million for the first quarter of fiscal 2021 compared to $17.2 million for the same period of fiscal 2020.Cost of Revenues: Cost of revenues for the first quarter of fiscal 2021 was $18.2 million... More